Andrea Gropman

Dr. Andrea Gropman


Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 November 2007 in Journal of Inherited Metabolic Disease
Verified
Journal Article
Closed access
PDF file
AGAndrea Gropman
Andrea Gropman
MSM. Summar
M. Summar
JLJ. V. Leonard
J. V. Leonard

4 April 2014 in Current Treatment Options in Neurology
Verified
Journal Article
Closed access
PDF file
SASreenivas Avula
Sreenivas Avula
SPSumit Parikh
Sumit Parikh
SDScott Demarest
Scott Demarest
JKJonathan Kurz
Jonathan Kurz
AGAndrea Gropman
Andrea Gropman

1 January 2010 in Molecular Genetics and Metabolism
Verified
Journal Article
Closed access
AGAndrea Gropman
Andrea Gropman

1 April 2013 in Neurotherapeutics
Verified
Journal Article
Closed access
PDF file
AGAndrea Gropman
Andrea Gropman

1 April 2007 in Current Opinion in Neurology
Verified
Journal Article
Closed access
AGAndrea Gropman
Andrea Gropman
SESarah H. Elsea
Sarah H. Elsea
WDWallace C Duncan
Wallace C Duncan
ASAnn Cm Smith
Ann Cm Smith
Recent clinical, neuroimaging, sleep, and molecular cytogenetic studies have provided new insights into the mechanisms leading to the Smith-Magenis phenotype and are summarized in this review. Cross sectional studies of patients with Smith-Magenis syndrome have found evidence for central and peripheral nervous system abnormalities, neurobehavioral disturbances, and an inverted pattern of melatonin secretion leading to circadian rhythm disturbance. A common chromosome 17p11.2 deletion interval spanning approximately 3.5 Mb is identified in about 70% of individuals with chromosome deletion. Recently heterozygous point mutations in the RAI1 gene within the Smith-Magenis syndrome critical region have been reported in Smith-Magenis syndrome patients without detectable deletion by fluorescent in-situ hybridization. Patients with intragenic mutations in RAI1 as well as those with deletions share most but not all aspects of the phenotype. Findings from molecular cytogenetic analysis suggest that other genes or genetic background may play a role in altering the functional availability of RAI1 for downstream effects. Further research into additional genes in the Smith-Magenis syndrome critical region will help define the role they play in modifying features or severity of the Smith-Magenis syndrome phenotype. More research is needed to translate advances in clinical research into new treatment options to address the sleep and neurobehavioral problems in this disorder.

1 September 2008 in Molecular Genetics and Metabolism
Verified
Journal Article
Closed access
AGAndrea Gropman
Andrea Gropman
SFS.T. Fricke
S.T. Fricke
RSR.R. Seltzer
R.R. Seltzer
AHA. Hailu
A. Hailu
AAA. Adeyemo
A. Adeyemo
MBM. Batshaw
M. Batshaw